Drugs / CD19-CAR(Mem) T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04881240 | Feb 2024 → Jul 2027 expected | childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR(Mem) T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04881240 ↗ |
| Modality | Cell therapy | “a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz” NCT04881240 ↗ |
| Route | Intravenous | “Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion” NCT04881240 ↗ |
| Target | CD19 | “CD19-specific CAR” NCT04881240 ↗ |